SCHEMBL352278

SCHEMBL352278

Cc1ccc(C(=O)NC2=CC(=O)C3OC3C2O)c(O)n1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PARK7 Q99497 1/20 0.49
GRM5 P41594 3/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
SORT1 Q99523 5/20 0.32
EGFR P00533 1/20 0.32
GAA P10253 2/20 0.31
NPC1 O15118 2/20 0.31
RAB9A P51151 2/20 0.31
MAPT P10636 1/20 0.31
ALDH1A1 P00352 2/20 0.31
HPGD P15428 2/20 0.31
HSD17B10 Q99714 2/20 0.31
POLB P06746 1/20 0.31
KDM4E B2RXH2 1/20 0.30
TP53 P04637 1/20 0.30
HTT P42858 1/20 0.30
RCE1 Q9Y256 1/20 0.30
L3MBTL1 Q9Y468 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL351687 0.83 PARK7 (0.48) PARK7GRM5
SCHEMBL666528 0.80 PARK7 (0.50) PARK7SMN1; SMN2GAANPC1RAB9A
SCHEMBL115782 0.79 PARK7 (0.51) PARK7SMN1; SMN2GAANPC1RAB9A
Dehydroxymethylepoxyquinomicin SCHEMBL14504317 0.78 PARK7 (0.54) PARK7SMN1; SMN2GAANPC1RAB9A
Dehydroxymethylepoxyquinomicin SCHEMBL14491796 0.78 PARK7 (0.54) PARK7SMN1; SMN2GAANPC1RAB9A
Dehydroxymethylepoxyquinomicin SCHEMBL1671089 0.78 PARK7 (0.54) PARK7SMN1; SMN2GAANPC1RAB9A
SCHEMBL352102 0.77 PARK7 (0.47) PARK7
SCHEMBL665471 0.77 PARK7 (0.57) PARK7GAANPC1RAB9AMAPT
SCHEMBL352808 0.76 PARK7 (0.46) PARK7
SCHEMBL666087 0.76 PARK7 (0.64) PARK7GAANPC1RAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2411376-B1 INHIBITORS OF NF-KB PROFECTUS BIOSCIENCES INC (US) 2015-04-22 EP claimed
US-8629164-B2 Inhibitors of NF-κB PROFECTUS BIOSCIENCES, INC. (US) 2014-01-14 US claimed
US-20120015952-A1 Inhibitors of NF-KB PROFECTUS BIOSCIENCES, INC. (US) 2012-01-19 US claimed
EP-2411376-B1 INHIBITORS OF NF-KB PROFECTUS BIOSCIENCES INC (US) 2015-04-22 EP disclosed
US-8629164-B2 Inhibitors of NF-κB PROFECTUS BIOSCIENCES, INC. (US) 2014-01-14 US disclosed
US-20120015952-A1 Inhibitors of NF-KB PROFECTUS BIOSCIENCES, INC. (US) 2012-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120015952-A1 Inhibitors of NF-KB NFKBIA, IKBKB, IKBKG PARK7 3327/4885GRM5 4441/4885SMN1; SMN2 4164/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.